RxDoctor Payments Data

Tracie Harris

Family · Scottsdale, AZNPI 1720608961

Payments from drug & device makers

$4,307in general payments, 2019–2025

Across 190 payments — averaging $22.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$862
  • AbbVie$661
  • Novo Nordisk$434
  • Boehringer Ingelheim$270
  • Takeda Pharmaceuticals U.S.A., Inc.$258
  • Amgen$236
  • plus $2K from 26 others

What the payments were for

  • Food & beverage$4,307100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,307 in reported general payments places this provider in the 90th percentile of 4,119 family providers in Arizona.

See all family providers in Arizona

Medicare billing

Part B allowed, 2024
$29,228
Medicare patients
103
Services billed
507

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide13$19,896
Levothyroxine Sodium66$683
SynthroidLevothyroxine Sodium12$642
Rosuvastatin Calcium53$537
Atorvastatin Calcium43$525
Lisinopril45$388
Cefdinir11$329
Gabapentin15$270
Pantoprazole Sodium14$234
Sertraline Hcl15$203
ValacyclovirValacyclovir Hcl12$161
Amlodipine Besylate21$155
Methylprednisolone24$149
Cephalexin13$145
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav17$140

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$434$19,89613 claims
AbbVieSynthroid$661$64212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,119 family providers in Arizona.

Other family in Scottsdale

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →